特拉维尔治疗

US · TVTX #2056 按市值排名上市于 1970

49.60 -3.19 -6.04%

实时 - 追踪5344个代码 - 心跳于145秒前 · 2026-10-16 19:30

✦ 量化股权信号计算方式说明

减持

最近一期（2026/Q3）披露持股的机构数量增加了2家。
机构持股总比例下降了0.5个百分点。

机构持股

机构持股比例: 115.34% -0.50pp
机构数量: 394 +2
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund76.58%

Hedge Fund20.98%

Public Company6.47%

VC/PE Fund5.80%

Private Company3.95%

Individual/Insider1.10%

Insurance Company0.81%

Government Pension Fund0.68%

主要股东截至 2026-06-30

Janus Henderson Group plc 12.01% · 11.32M 股

BlackRock 8.51% · 8.02M 股

FMR 6.51% · 6.14M 股

Vanguard Capital Management, LLC 5.06% · 4.77M 股

State Street Global Advisors 4.52% · 4.26M 股

Bank of America Corporation 4.17% · 3.93M 股

Perceptive Advisors LLC 3.98% · 3.75M 股

Macquarie Investment Management Business Trust 2.98% · 2.81M 股

Emerald Advisers, LLC 2.79% · 2.63M 股

Adage Capital Management, L.P. 2.73% · 2.57M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 18次买入 · 32次卖出

姓名	职务	持股比例
Eric Dube	Chief Executive Officer	0.16%
Elizabeth Reed	Senior Vice President	0.11%
Jula Inrig	Chief Medical Officer	0.11%
Jeffrey Meckler	Independent Director	0.10%
Christopher Cline	Chief Financial Officer	0.09%
William Rote	Senior VP and Head of Research & Development	0.07%
Gary Lyons	Independent Chairperson	0.07%
Peter Heerma	Chief Commercial Officer	0.07%
Timothy Coughlin	Independent Director	0.06%
Sandra Calvin	SVP, Corporate Controller & Chief Accounting Officer	0.04%

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-09-16	Eric Dube	Chief Executive Officer	Derivative Exercise and Sale	-400,000	$23.34–65.31
2026-09-16	Eric Dube	Chief Executive Officer	Intent to Sell (Form 144)	-108,493	$63.48
2026-09-16	Peter Heerma	Chief Commercial Officer	Derivative Exercise and Sale	-258,189	$8.93–65.07
2026-09-16	Peter Heerma	Chief Commercial Officer	Intent to Sell (Form 144)	-8,282	$63.48
2026-09-15	William Rote	Senior VP and Head of Research & Development	Intent to Sell (Form 144)	-112,850	$62.51
2026-09-15	Eric Dube	Chief Executive Officer	Intent to Sell (Form 144)	-195,841	$62.51
2026-09-15	Peter Heerma	Chief Commercial Officer	Intent to Sell (Form 144)	-172,717	$62.51
2026-09-14	Elizabeth Reed	Senior Vice President	Derivative Exercise and Sale	-37,500	$15.46–65.31
2026-09-14	William Rote	Senior VP and Head of Research & Development	Intent to Sell (Form 144)	-96,198	$65.79
2026-09-14	Christopher Cline	Chief Financial Officer	Automatic Disposition	-30,508	$62.00–65.31
2026-09-14	Christopher Cline	Chief Financial Officer	Derivative Exercise and Sale	-20,000	$17.44–62.00
2026-09-14	Eric Dube	Chief Executive Officer	Intent to Sell (Form 144)	-95,666	$65.79
2026-09-14	Peter Heerma	Chief Commercial Officer	Automatic Disposition	-25,000	$62.59–65.31
2026-09-14	Sandra Calvin	SVP, Corporate Controller & Chief Accounting Officer	Derivative Exercise and Sale	-5,375	$20.46–63.66
2026-09-14	Jula Inrig	Chief Medical Officer	Automatic Disposition	-12,279	$62.62–65.31
2026-09-14	Jula Inrig	Chief Medical Officer	Derivative Exercise and Sale	-32,395	$8.93–62.62
2026-09-09	Jeffrey Meckler	Independent Director	Derivative Exercise and Sale	-20,000	$17.44–68.09
2026-09-01	Christopher Cline	Chief Financial Officer	Open Market Disposition	-642	$66.37
2026-08-17	Gary Lyons	Independent Chairperson	Derivative Exercise and Sale	-10,000	$17.44–64.16
2026-08-17	Gary Lyons	Independent Chairperson	Intent to Sell (Form 144)	-5,000	$63.53

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。